

# EMSP repository of MS relevant health policy initiatives 2011-2016

## MS in the 21st Century

- Peter Rieckman (Neurologist) – (Chair) – funded by Merck

## MS Calls for action – Pan –European multi-stakeholder colloquia

- Prof. Patrick Vermersch (Neurologist) – funded by Teva

## EMA Guidelines on clinical investigation of medicinal products for the treatment of MS

- EMA and public consultation

## MS Nurse PRO

- Multiple Sclerosis-Nurse Empowering EDucation (MS-NEED): EMSP, multi-sponsored

## Recommendations on rehabilitation services for persons with MS in Europe

- EMSP, funded by European Union 2012 Work Programme

# MS health policy initiatives 2011-2016

Consensus Statement – Evaluation of new & existing therapies for paediatric MS in Europe

- International Pediatric Multiple Sclerosis Study Group (IPMSSG)

The State of MS (part I)- Identifying factors which restrict access to MS treatments in Europe

- State of MS Consortium, sponsored by Biogen

The State of MS (part II) – A global study among MS patients and neurologists

- Nielsen and State of MS Consortium, sponsored by Biogen

The State of MS – Cost of disease

- London School of Economics, sponsored by Roche

Multiple Sclerosis Consumer Survey

- Galliard Healthcare Communications, sponsored by Novartis

# MS health policy initiatives 2011-2016

## BRAIN HEALTH – TIME MATTERS IN MULTIPLE SCLEROSIS

- Pharmaco-Genesis, multi-sponsored

## OFF-LABEL - OFF-LABEL USE OF MEDICINAL PRODUCTS IN THE EU

- EUROPEAN PUBLIC HEALTH ALLIANCE , sponsored by EU

## New Clinical Guidelines on Multiple Sclerosis

- ECTRIMS + EAN

\*Do any of these projects overlap with our proposed activities?

\*\*Do any gaps need action? If so, do they chime with the objectives of this group?